GURU.Markets stock price, segment price, and overall market index valuation
The company's share price GeoVax Labs Inc.
GeoVax is a biotech company developing vaccines. Its stock price is highly volatile, driven by news about the clinical trials of its vaccine candidates against various infectious diseases and cancer.
Share prices of companies in the market segment - Pharma immune
GeoVax Labs is a biotech company developing immunotherapeutics and vaccines for cancer and infectious diseases based on its MVA-VLP platform. We've categorized it as a Pharmaceuticals company: Immunology. The chart below shows how the market values companies with vaccine platforms.
Broad Market Index - GURU.Markets
GeoVax Labs is a biotech company developing vaccines against infectious diseases and cancer based on its unique platform. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how GeoVax shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
GOVX - Daily change in the company's share price GeoVax Labs Inc.
GeoVax Labs, Inc.'s daily price change reflects the extreme volatility inherent in biotech companies. This metric measures its sensitivity to news about clinical trials of its infectious disease and cancer vaccines.
Daily change in the price of a set of shares in a market segment - Pharma immune
GeoVax Labs, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with GOVX, which focuses on vaccines, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
GeoVax Labs is a biotech company developing vaccines against infectious diseases and cancer. Its shares are extremely sensitive to news about clinical trials and pandemics. This event-driven volatility is a clear example of how biotech influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization GeoVax Labs Inc.
GeoVax Labs, Inc.'s year-to-date performance is a story about the development of its vaccine platform. Its 12-month market cap depends entirely on progress in clinical trials of its COVID-19, HIV, and cancer vaccines. Success in any of these areas could be a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Pharma immune
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines against infectious diseases and cancer. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
GeoVax Labs is a classic biotech company whose value is locked into the vaccine pipeline. Its shares move with news about clinical trials, not economic cycles. A sharp rise or fall amid a calm market is clear evidence that investors are betting solely on a scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization GeoVax Labs Inc.
GeoVax is a biotech company developing vaccines. Its monthly performance is entirely dependent on progress in its clinical trials. News of its infectious disease and cancer vaccine trials are the main drivers of its price.
Monthly dynamics of market capitalization of the market segment - Pharma immune
GeoVax Labs is a biotechnology company developing vaccines against infectious diseases (such as COVID-19 and HIV) and cancer based on its unique platform. The chart below illustrates the overall dynamics in the immunology sector, where innovative vaccine technologies are key to combating the most challenging diseases.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies developing vaccines can surge or fall on trial news, ignoring the market. The chart below shows the general trends. Is GeoVax Labs moving at its own pace?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization GeoVax Labs Inc.
GeoVax, a biotech company developing vaccines based on its unique MVA-VLP platform, is extremely news-sensitive. Its weekly stock price is a direct reaction to the release of clinical trial data for its vaccines against infectious diseases (COVID-19, Mpox) and cancer.
Weekly dynamics of market capitalization of the market segment - Pharma immune
GeoVax operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire sector. The chart will reveal whether GOVX is moving with the industry or whether its vaccine platform is creating its own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
GeoVax Labs, Inc., as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how GOVX shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
GOVX - Market capitalization of the company GeoVax Labs Inc.
GeoVax Labs's market capitalization is a story about the search for vaccines against the most complex diseases, such as HIV and cancer. This biotech company's stock price reflects investor hopes for its unique vaccine platform. Its speculative dynamics reflect the market's assessment of its scientific data and the long, risky path to success.
GOVX - Share of the company's market capitalization GeoVax Labs Inc. within the market segment - Pharma immune
GeoVax Labs develops vaccines and immunotherapeutics based on its unique MVA-VLP platform. Its market share is based on the potential of this technology. The chart shows how the market perceives its ability to develop vaccines against complex targets such as HIV and cancer.
Market capitalization of the market segment - Pharma immune
GeoVax Labs develops vaccines and immunotherapeutic drugs against cancer and infectious diseases. The chart below shows the market capitalization of the immunological pharmaceutical sector. This represents an industry seeking new ways to "train" the immune system to fight disease.
Market capitalization of all companies included in a broad market index - GURU.Markets
GeoVax is a biotech company developing vaccines against infectious diseases and cancer based on its MVA-VLP platform. Its market capitalization is a bet on this technology. The chart below shows the economic weight of companies working on new vaccines.
Book value capitalization of the company, segment and market as a whole
GOVX - Book value capitalization of the company GeoVax Labs Inc.
GeoVax Labs' foundation is its vaccine development platform. The company's book value reflects its patents for the MVA-VLP technology, which enables the development of vaccines against infectious diseases (COVID-19, HIV) and cancer, as well as its R&D capital. The chart below shows the financial foundation upon which these important scientific advances are built.
GOVX - Share of the company's book capitalization GeoVax Labs Inc. within the market segment - Pharma immune
GeoVax Labs, Inc., a biopharmaceutical company, is focused on vaccine R&D. Its laboratories are its primary physical asset. The S_BCap_Seg chart shows its small share of physical infrastructure, which is typical for a company in the research stage.
Market segment balance sheet capitalization - Pharma immune
GeoVax Labs is a biotech company developing vaccines. Its value lies in its unique MVA viral platform. A book value chart shows that its assets are almost entirely intangible, reflecting a focus on research rather than mass production.
Book value of all companies included in the broad market index - GURU.Markets
GeoVax Labs' assets comprise a vaccine development platform. The company's book value reflects its R&D laboratories and the rights to its MVA-VLP technology, which enables the development of vaccines against cancer and infectious diseases such as HIV and COVID-19. This provides the foundation for the creation of a new generation of immunotherapeutics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - GeoVax Labs Inc.
GeoVax Labs is a biotech company developing vaccines, including for COVID-19 and cancer. Its book value is derived from R&D. Its market capitalization is a highly volatile bet on the success of its vaccine platform in clinical trials.
Market to book capitalization ratio in a market segment - Pharma immune
GeoVax Labs is a biotech company developing vaccines, including those for COVID-19 and HIV. Its value lies in its scientific platform. The chart shows how market expectations for its vaccine candidates compare to its tangible assets.
Market to book capitalization ratio for the market as a whole
GeoVax Labs is a biotech company developing vaccines and immunotherapies against infectious diseases and cancer. Its value depends almost entirely on the success of its scientific platform. The chart below demonstrates how its market valuation reflects investor confidence in its breakthrough technology.
Debts of the company, segment and market as a whole
GOVX - Company debts GeoVax Labs Inc.
GeoVax Labs, a biotech company developing vaccines, is using debt to finance its clinical programs. This chart shows how the company is raising capital to conduct trials of its vaccines against COVID-19, HIV, and other infectious diseases, as well as oncology.
Market segment debts - Pharma immune
GeoVax Labs is a clinical-stage biotechnology company developing vaccines against infectious diseases and cancer. Vaccine development is a long, expensive, and risky process. This chart shows its financial reserves, which determine its ability to continue its research programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio GeoVax Labs Inc.
GeoVax Labs is a biotech company developing vaccines, including those against infectious diseases and cancer. This chart shows whether it uses debt for its research. For a company in the development stage, where success is uncertain, debt is a high-risk factor that could impact its ability to complete trials.
Market segment debt to market segment book capitalization - Pharma immune
GeoVax Labs is a biotech company developing vaccines, including those against infectious diseases and cancer. This chart for the biotech sector shows how the industry as a whole raises capital to fund lengthy and expensive research. It provides context for assessing the company's financial strength.
Debt to book value of all companies in the market
GeoVax Labs is a biotech company developing vaccines and immunotherapeutics against infectious diseases and cancer. This chart, showing the market's debt-to-book value ratio, is important for assessing the investment climate. The market's willingness to finance companies with long and expensive vaccine development cycles determines GeoVax's future.
P/E of the company, segment and market as a whole
P/E - GeoVax Labs Inc.
GeoVax Labs is a biotech company developing vaccines against infectious diseases and cancer. This chart is an indicator of confidence in its vaccine platform. Its dynamics are heavily dependent on clinical trial results. Successful data for one of the vaccine candidates could trigger explosive growth, reflecting the huge potential market.
P/E of the market segment - Pharma immune
GeoVax Labs, Inc. is a biotech company. This chart shows the average P/E for the biotech sector. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its vaccine platform compared to the average prospects of other biotech companies.
P/E of the market as a whole
GeoVax Labs is a biotech company developing vaccines against infectious diseases and cancer using its unique platform. This chart shows sentiment in the biotech sector. The company's valuation is based on the potential of its technology platform and is highly sensitive to news about preclinical and clinical trial results.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company GeoVax Labs Inc.
GeoVax Labs is a biotechnology company developing vaccines against infectious diseases and cancer. The chart shows speculative expectations for future revenue, which are entirely dependent on the success of clinical trials of its vaccine candidates.
%20P%2FE%20GeoVax%20Labs%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-GeoVax-Labs-Inc.&v=1772640086727 "Chart of the company's future (projected) P/E GeoVax Labs Inc.")
Future (projected) P/E of the market segment - Pharma immune
GeoVax Labs develops vaccines and immunotherapies for infectious diseases and cancer using its unique MVA-VLP platform. This chart shows its future profitability expectations, allowing us to assess how highly the market values its technology and clinical pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772640086734 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
GeoVax Labs is a biotech company developing vaccines against infectious diseases and cancer. Its valuation is a bet on the success of its unique MVA-VLP platform. It doesn't correlate with overall market forecasts, but depends solely on clinical trial data and regulatory decisions.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772640086769 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit GeoVax Labs Inc.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines against infectious diseases and cancer immunotherapies. Its financial indicators reflect research and development expenses. This chart illustrates the investment required to bring new vaccines to market, a long and capital-intensive process.
Profit of companies in the market segment - Pharma immune
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapeutics against infectious diseases and cancer. This chart shows the profitability of the immunology segment. R&D costs impact current overall profitability, but its unique platform could lead to the creation of next-generation vaccines.
Overall market profit
GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapeutics against infectious diseases and cancer. Its value and future depend solely on the success of its research. This chart illustrates general economic cycles, which do not affect the underlying logic of development or the potential of GeoVax's vaccine portfolio.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company GeoVax Labs Inc.
GeoVax Labs is a biotech company developing vaccines and immunotherapies against cancer and infectious diseases, including HIV and COVID-19. This chart reflects analysts' future earnings expectations, based on the long-term potential of its MVA vaccine platform. It demonstrates the market's confidence in the success of the company's clinical trials.
%20profit%20of%20the%20company%20GeoVax%20Labs%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-GeoVax-Labs-Inc.&v=1772640086851 "Graph of future (projected) profit of the company GeoVax Labs Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines against infectious diseases and cancer. This chart shows revenue projections for the immunology pharmaceutical segment. It reflects expectations for new vaccine platforms that can provide protection against a broad range of threats.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772640086928 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
GeoVax Labs develops vaccines and immunotherapies. For a biotech company at this stage, the market's profit forecast is an indicator of capital availability. The optimistic forecast, as seen in the chart, suggests that investors will be more willing to fund risky but potentially life-saving clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772640086956 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - GeoVax Labs Inc.
GeoVax Labs, Inc. is a biotechnology company developing vaccines against infectious diseases and cancer. Currently in the clinical stage, it has no sales revenue. Its P/S will become key after commercialization, reflecting the market valuation of its vaccine platform.
P/S market segment - Pharma immune
GeoVax Labs, Inc. is a biotechnology company developing immunotherapeutics and vaccines against cancer and infectious diseases using its unique MVA-VLP platform. This chart reflects how the market values their scientific platform and development pipeline, placing a premium on the potential for future revenue from breakthrough vaccines.
P/S of the market as a whole
GeoVax Labs develops vaccines and immunotherapies for the treatment of infectious diseases and cancer. The company has no commercial revenue, and its valuation depends on the success of clinical trials. This chart, showing its estimated real revenue, highlights GeoVax's high-risk bet on scientific development.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company GeoVax Labs Inc.
GeoVax Labs is a biotech company developing vaccines against infectious diseases and cancer using its unique platform. This chart reflects investor expectations for future revenue from the commercialization of its vaccine candidates, assuming they successfully complete clinical trials and receive regulatory approval.
%20P%2FS%20GeoVax%20Labs%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-GeoVax-Labs-Inc.&v=1772640087251 "The graph of the company's future (projected) P/S GeoVax Labs Inc.")
Future (projected) P/S of the market segment - Pharma immune
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines against infectious diseases and cancer based on its MVA-VLP platform. This chart shows how the market assesses the future commercial potential of its vaccine candidates. It compares it to other immunology companies, reflecting the confidence in its technology.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772640087272 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
GeoVax Labs is a biotech company developing vaccines against infectious diseases (including COVID-19 and HIV) and immunotherapies for cancer treatment. This chart illustrates general revenue expectations, and GOVX shows how the pandemic has heightened interest in vaccine technologies and their potential to address global health challenges.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772640087290 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales GeoVax Labs Inc.
GeoVax Labs, Inc. is a clinical-stage biotechnology company specializing in the development of vaccines against infectious diseases and cancer. The company currently has no commercial products, and its revenue (as shown in this chart) is generated primarily from government grants and R&D contracts.
Sales of companies in the market segment - Pharma immune
GeoVax Labs is a biotech company developing vaccines and immunotherapeutic drugs. At this stage, its revenue is likely derived from government grants and contracts. This chart allows investors to assess the level of government support for its developments.
Overall market sales
GeoVax Labs, Inc. is a biotechnology company developing vaccines against infectious diseases and cancer. Its success depends on the results of clinical trials and the epidemiological situation. This chart does not apply to GeoVax, whose value is determined by scientific data and the potential of its vaccine platform.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company GeoVax Labs Inc.
GeoVax Labs is a biotech company developing vaccines against infectious diseases and cancer. Its revenue forecast is dependent on the success of clinical trials and the receipt of funding or partnerships. This chart reflects analysts' speculative expectations for its MVA vaccine platform.
%20sales%20of%20the%20company%20GeoVax%20Labs%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-GeoVax-Labs-Inc.&v=1772640087386 "Schedule of future (projected) sales of the company GeoVax Labs Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
GeoVax Labs is a biotechnology company developing vaccines and immunotherapeutics. This chart shows projected revenue for the entire immunology segment. It helps assess investor interest and the potential market for new vaccines against infectious diseases and cancer, which is key to assessing the prospects of the GeoVax platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772640087403 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
GeoVax Labs is a biotech company developing vaccines against infectious diseases and cancer. Its future depends on the success of clinical trials and government vaccination programs. This graph of overall market expectations reflects the investment climate. A positive environment facilitates raising the capital needed to finance long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772640087411 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality GeoVax Labs Inc.
GeoVax Labs is a biotech company developing vaccines against infectious diseases and cancer. This chart reflects its current status in clinical trials. It doesn't show revenue, but rather the level of investment in its platform, the success of which determines its future.
Market segment marginality - Pharma immune
GeoVax Labs, Inc. is a biotechnology company developing immunotherapeutics and vaccines against cancer and infectious diseases using its unique MVA-VLP platform. This chart reflects the average profitability in the immunology sector and provides an idea of the potential commercial value of GeoVax's technology if its developments are successful.
Market marginality as a whole
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines, including those for COVID-19 and cancer. Its value reflects the company's hopes for success in research. This market return chart has no bearing on GeoVax's valuation, which depends solely on scientific data and regulatory decisions.
Employees in the company, segment and market as a whole
Number of employees in the company GeoVax Labs Inc.
GeoVax Labs is a biotech company developing vaccines and immunotherapeutics. Its small scientific team uses its unique platform to create vaccines against infectious diseases and cancer. This chart shows the size of its focused R&D team working at the forefront of science.
Share of the company's employees GeoVax Labs Inc. within the market segment - Pharma immune
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer. This chart illustrates its scientific potential. It reflects the proportion of virologists and immunologists working with GeoVax to create the next generation of vaccines using its unique platform.
Number of employees in the market segment - Pharma immune
GeoVax Labs, Inc. is a biotechnology company developing vaccines and immunotherapeutics. This chart shows employment in the immunology sector. The growing number of scientists in this field reflects the increased focus on infectious disease prevention and the development of new vaccine platforms capable of rapidly responding to emerging threats.
Number of employees in the market as a whole
GeoVax Labs, Inc. is a biotechnology company specializing in the development of vaccines against infectious diseases and cancer. Vaccine development is a strategically important area for global health. This chart shows overall employment, and these companies are at the forefront of the fight against new and existing health threats.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company GeoVax Labs Inc. (GOVX)
GeoVax Labs is a biopharmaceutical company in the R&D stage. Its value is determined by investor expectations. This chart illustrates the enormous value the market places on each scientist and their research. It's a valuation of intellectual capital in its most concentrated form—at the vaccine development stage.
%20of%20the%20company%20GeoVax%20Labs%20Inc.%20(GOVX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-GeoVax-Labs-Inc.-GOVX&v=1772640087658 "Chart of market capitalization per employee (in thousands of dollars) of the company GeoVax Labs Inc. (GOVX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
GeoVax Labs develops vaccines and immunotherapeutic drugs. For a biotech company in the R&D stage, market capitalization per employee reflects investors' faith in its scientific platform. A high market capitalization per employee indicates high expectations for clinical trial results.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772640087677 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
GeoVax Labs is a biotech company developing vaccines and immunotherapeutics. Vaccine development is a long and risky process. This chart shows how investors view the company's scientific platform and its team's potential to create new, effective vaccines against infectious diseases and cancer.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772640087767 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company GeoVax Labs Inc. (GOVX)
GeoVax Labs is a biotech company developing vaccines (including for COVID and MPOX) and cancer immunotherapy. It's an R&D company. This chart, in negative territory, shows how much capital is being burned per scientist working on these vaccines in a highly competitive environment.
%20Chart%20GeoVax%20Labs%20Inc.%20(GOVX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-GeoVax-Labs-Inc.-GOVX&v=1772640087834 "Company Profit Per Employee (in thousands of dollars) Chart GeoVax Labs Inc. (GOVX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
GeoVax Labs, Inc. is a biotech company developing vaccines and immunotherapies against infectious diseases and cancer. This chart illustrates the potential value of their scientific platform. It shows the enormous profit potential of a single successful vaccine developed by a small team of scientists, a key metric for biotech investors.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772640087914 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
GeoVax Labs, Inc. is a biotechnology company developing vaccines (including those for COVID-19 and HIV) and cancer immunotherapy. It is a clinical-stage R&D company. This chart reflects the "cost" of science—the investment (expense) per scientist required to develop and advance vaccines through expensive clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772640087973 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee GeoVax Labs Inc. (GOVX)
GeoVax Labs, Inc. is a clinical-stage biotech company developing vaccines. This graph, showing zero revenue per employee, is typical for the sector. It reflects investment in research. Success in clinical trials and subsequent contracts could lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-GeoVax-Labs-Inc.-GOVX&v=1772640088058 "Sales chart per company employee GeoVax Labs Inc. (GOVX)")
Sales per employee in the market segment - Pharma immune
GeoVax Labs (GOVX) is a biotech company developing vaccines (including those for COVID-19 and Lassa fever) and cancer immunotherapy based on its MVA-VLP platform. This chart shows the average revenue per employee in the pharmaceutical segment. For GeoVax, which is in the R&D stage, comparing to this benchmark (zero) underscores their focus on science.
Sales per employee for the market as a whole
GeoVax Labs (GOVX) is a clinical-stage biotech company developing vaccines (COVID-19, oncology). No revenue. This metric is irrelevant. The company's entire value lies in the potential of its vaccine platform (MVA-VLP) and clinical trial data.
Short shares by company, segment and market as a whole
Shares shorted by company GeoVax Labs Inc. (GOVX)
GeoVax Labs is a biotech company developing vaccines (including COVID and cancer) using its MVA-VLP platform. This chart shows the odds on their platform's failure. Bears believe the company is hopelessly late with a COVID vaccine, and its oncology development is at an early and risky stage.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-GeoVax-Labs-Inc.-GOVX&v=1772640088333 "Short Shares Chart for the Company GeoVax Labs Inc. (GOVX)")
Shares shorted by market segment - Pharma immune
GeoVax Labs (GOVX) is a biotech company developing vaccines (including COVID and oncology) using its MVA-VLP platform. This chart highlights the pessimism in the sector. The surge in shorts across the sector is a bet that GOVX is late to the COVID party. Investors don't believe the company can compete with giants like Pfizer and Moderna and doubt the effectiveness of its platform in oncology.
Shares shorted by the overall market
GeoVax (GOVX) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing GOVX will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator GeoVax Labs Inc. (GOVX)
GeoVax Labs is a biotech company developing vaccines against infectious diseases (including COVID) and cancer. This chart represents the "pulse" of epidemics. The "temperature" of investor interest "overheats" during any new health threat and "cools" when the news agenda shifts.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-GeoVax-Labs-Inc.-GOVX&v=1772640088559 "RSI 14 indicator chart for the company's stock GeoVax Labs Inc. (GOVX)")
RSI 14 Market Segment - Pharma immune
GeoVax Labs is a clinical-stage biotech company developing the MVA-VLP platform for vaccines against infectious diseases (COVID, MPOX) and cancer immunotherapy. This chart reflects the overall sentiment in the biotech sector and helps assess how the market views this speculative industry.
RSI 14 for the overall market
GeoVax Labs (GOVX) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GOVX (GeoVax Labs Inc.)
GeoVax Labs (GOVX) is a biotech company developing vaccines against infectious diseases (HIV, COVID, Mpox) and cancer based on its MVA-VLP platform. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of this vaccine technology and its clinical success.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GOVX-GeoVax-Labs-Inc.&v=1772640088717 "A chart showing analyst consensus forecasts for the expected stock price. GOVX (GeoVax Labs Inc.)")
The difference between the consensus estimate and the actual stock price GOVX (GeoVax Labs Inc.)
GeoVax Labs is a biotech company developing vaccines (MVA-VLP platform) against infectious diseases (COVID-19, HIV) and cancer. This chart shows the difference between the market valuation and the consensus estimate. It indicates whether experts believe in their R&D platform and their chances of approval.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GOVX-GeoVax-Labs-Inc.&v=1772640088788 "A chart showing the difference between the consensus forecast and the actual stock price. GOVX (GeoVax Labs Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
GeoVax Labs is a biotech company using its R&D platform (MVA) to develop vaccines against infectious diseases (including COVID-19) and cancer. This chart reflects analyst expectations across the immunopharmaceuticals sector, demonstrating whether experts believe new vaccine technologies will be successful.
Analysts' consensus forecast for the overall market share price
GeoVax Labs is a biotech company developing a platform for vaccines against infectious diseases (COVID, MVA) and cancer. This chart shows the overall market "risk appetite." For GeoVax, a high-risk clinical-stage company, overall market optimism (the rising chart) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index GeoVax Labs Inc.
GeoVax Labs is a clinical-stage biotech company focused on vaccine R&D. Their platform (MVA-VLP) is used to create vaccines against complex targets (HIV, COVID-19, cancer). This chart is a pure indicator of confidence in their R&D. It doesn't reflect revenue, but rather a speculative estimate of their (very risky) pipeline and their chances of success in clinical trials.
AKIMA Market Segment Index - Pharma immune
GeoVax Labs (GOVX) is a biotech company developing vaccines and immunotherapeutics. Their platform (MVA-VLP) is used to create vaccines against COVID-19, cancer, and other infectious diseases. The chart shows the average index for the segment, helping investors assess how this platform company compares to the average risk in the sector.
The AKIM Index for the overall market
GeoVax Labs is a biotech company developing vaccines against infectious diseases (COVID, monkeypox) and cancer using the MVA vector platform. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this vaccine story compares to overall economic trends and health threats.
